JP7482152B2 - 皮膚疾患の処置のためのピリミジンｊａｋ阻害剤 発明の背景 - Google Patents

皮膚疾患の処置のためのピリミジンｊａｋ阻害剤 発明の背景 Download PDF

Info

Publication number
JP7482152B2
JP7482152B2 JP2021562812A JP2021562812A JP7482152B2 JP 7482152 B2 JP7482152 B2 JP 7482152B2 JP 2021562812 A JP2021562812 A JP 2021562812A JP 2021562812 A JP2021562812 A JP 2021562812A JP 7482152 B2 JP7482152 B2 JP 7482152B2
Authority
JP
Japan
Prior art keywords
pharma
mmol
acceptable salt
ceutically acceptable
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021562812A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022529371A (ja
JP2022529371A5 (https=
Inventor
フィリップ エー． ガーケン，
ジャンフア チャオ，
Original Assignee
セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー filed Critical セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー
Publication of JP2022529371A publication Critical patent/JP2022529371A/ja
Publication of JP2022529371A5 publication Critical patent/JP2022529371A5/ja
Application granted granted Critical
Publication of JP7482152B2 publication Critical patent/JP7482152B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2021562812A 2019-04-24 2020-04-23 皮膚疾患の処置のためのピリミジンｊａｋ阻害剤 発明の背景 Active JP7482152B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962837827P 2019-04-24 2019-04-24
US62/837,827 2019-04-24
PCT/US2020/029466 WO2020219640A1 (en) 2019-04-24 2020-04-23 Pyrimidine jak inhibitors for the treatment of skin diseases

Publications (3)

Publication Number Publication Date
JP2022529371A JP2022529371A (ja) 2022-06-21
JP2022529371A5 JP2022529371A5 (https=) 2023-04-04
JP7482152B2 true JP7482152B2 (ja) 2024-05-13

Family

ID=70779856

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021562812A Active JP7482152B2 (ja) 2019-04-24 2020-04-23 皮膚疾患の処置のためのピリミジンｊａｋ阻害剤 発明の背景

Country Status (11)

Country Link
US (1) US11439641B2 (https=)
EP (1) EP3959213B1 (https=)
JP (1) JP7482152B2 (https=)
AR (1) AR118767A1 (https=)
CA (1) CA3135388A1 (https=)
ES (1) ES2994097T3 (https=)
HR (1) HRP20241053T1 (https=)
HU (1) HUE067909T2 (https=)
PL (1) PL3959213T3 (https=)
TW (1) TW202106681A (https=)
WO (1) WO2020219640A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202001706RA (en) 2017-10-27 2020-03-30 Theravance Biopharma R&D Ip Llc Pyrimidine compound as jak kinase inhibitor
WO2020108613A1 (zh) * 2018-11-30 2020-06-04 江苏豪森药业集团有限公司 杂芳类衍生物调节剂、其制备方法和应用
PL3958969T3 (pl) 2019-04-24 2024-05-20 Theravance Biopharma R&D Ip, Llc Estrowe i węglanowe związki pirymidynowe jako inhibitory kinaz
CN116390922B (zh) * 2020-10-21 2025-07-18 珠海联邦制药股份有限公司 硒杂环类化合物及其应用
WO2022094174A1 (en) * 2020-10-30 2022-05-05 Children's Hospital Medical Center Compositions and methods for the treatment of esophageal conditions
JP2024516299A (ja) * 2021-05-03 2024-04-12 インサイト・コーポレイション 結節性痒疹の治療のためのルキソリチニブ
UA129643C2 (uk) 2021-05-03 2025-06-18 Інсайт Корпорейшн Інгібітори шляху jak1 для лікування вузлуватого свербця
WO2023202706A1 (zh) * 2022-04-21 2023-10-26 南京明德新药研发有限公司 硒杂环类化合物的盐型和晶型及其应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016191524A1 (en) 2015-05-28 2016-12-01 Theravance Biopharma R&D Ip, Llc Naphthyridine compounds as jak kinase inhibitors
WO2017189822A1 (en) 2016-04-28 2017-11-02 Theravance Biopharma R&D Ip, Llc Pyrimidine compounds as jak kinase inhibitors
WO2018086547A1 (zh) 2016-11-10 2018-05-17 浙江大学 2-取代芳环-嘧啶类衍生物及制备和应用
WO2019084383A1 (en) 2017-10-27 2019-05-02 Theravance Biopharma R&D Ip, Llc PYRIMIDINE COMPOUNDS AS JAK KINASE INHIBITORS

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4919934A (en) 1989-03-02 1990-04-24 Richardson-Vicks Inc. Cosmetic sticks
US6660731B2 (en) 2000-09-15 2003-12-09 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
WO2002022605A1 (en) 2000-09-15 2002-03-21 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US6989385B2 (en) 2000-12-21 2006-01-24 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US20070179125A1 (en) 2005-11-16 2007-08-02 Damien Fraysse Aminopyrimidines useful as kinase inhibitors
TW200817391A (en) 2006-06-30 2008-04-16 Astrazeneca Ab Novel compounds
EP2043651A2 (en) 2006-07-05 2009-04-08 Exelixis, Inc. Methods of using igf1r and abl kinase modulators
CN104011050A (zh) 2011-12-22 2014-08-27 霍夫曼-拉罗奇有限公司 作为丝氨酸/苏氨酸激酶抑制剂的2,4-二氨基-嘧啶衍生物
WO2015094803A1 (en) 2013-12-16 2015-06-25 Calitor Sciences, Llc Substituted heteroaryl compounds and methods of use
NO2721710T3 (https=) 2014-08-21 2018-03-31
WO2020108516A1 (zh) 2018-11-27 2020-06-04 江苏豪森药业集团有限公司 含氮杂芳类衍生物调节剂、其制备方法和应用
WO2020108613A1 (zh) 2018-11-30 2020-06-04 江苏豪森药业集团有限公司 杂芳类衍生物调节剂、其制备方法和应用
PL3958969T3 (pl) * 2019-04-24 2024-05-20 Theravance Biopharma R&D Ip, Llc Estrowe i węglanowe związki pirymidynowe jako inhibitory kinaz
CN113372364B (zh) 2020-03-10 2024-05-31 明慧医药（上海）有限公司 一类jak激酶抑制剂及其制备和应用
CN113372351A (zh) 2020-03-10 2021-09-10 明慧医药（杭州）有限公司 一类jak激酶抑制剂及其制备和应用

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016191524A1 (en) 2015-05-28 2016-12-01 Theravance Biopharma R&D Ip, Llc Naphthyridine compounds as jak kinase inhibitors
WO2017189822A1 (en) 2016-04-28 2017-11-02 Theravance Biopharma R&D Ip, Llc Pyrimidine compounds as jak kinase inhibitors
WO2018086547A1 (zh) 2016-11-10 2018-05-17 浙江大学 2-取代芳环-嘧啶类衍生物及制备和应用
WO2019084383A1 (en) 2017-10-27 2019-05-02 Theravance Biopharma R&D Ip, Llc PYRIMIDINE COMPOUNDS AS JAK KINASE INHIBITORS

Also Published As

Publication number Publication date
EP3959213A1 (en) 2022-03-02
TW202106681A (zh) 2021-02-16
ES2994097T3 (en) 2025-01-17
CA3135388A1 (en) 2020-10-29
PL3959213T3 (pl) 2024-11-04
HUE067909T2 (hu) 2024-11-28
US20200338073A1 (en) 2020-10-29
AR118767A1 (es) 2021-10-27
WO2020219640A1 (en) 2020-10-29
JP2022529371A (ja) 2022-06-21
EP3959213C0 (en) 2024-06-05
EP3959213B1 (en) 2024-06-05
US11439641B2 (en) 2022-09-13
HRP20241053T1 (hr) 2024-11-08

Similar Documents

Publication Publication Date Title
JP7482152B2 (ja) 皮膚疾患の処置のためのピリミジンｊａｋ阻害剤 発明の背景
JP7470713B2 (ja) Ｊａｋキナーゼ阻害剤としてのエステルおよびカルボナートピリミジン化合物
US12172994B2 (en) Pyrimidine compound as JAK kinase inhibitor
CA3020506A1 (en) Pyrimidine compounds as jak kinase inhibitors
CA3125039A1 (en) Imidazo[1,5-a]pyridine, 1,2,4-triazolo[4,3-a]pyridine and imidazo[1,5-a]pyrazine as jak inhibitors
OA19911A (en) Pyrimidine compound as JAK kinase inhibitor.
HK40029509B (en) Pyrimidine compound as jak kinase inhibitor
HK40029509A (en) Pyrimidine compound as jak kinase inhibitor
EA041115B1 (ru) Пиримидиновое соединение в качестве ингибитора jak киназы

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230327

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230327

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240401

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240426

R150 Certificate of patent or registration of utility model

Ref document number: 7482152

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150